Home › Gastrointestinal Stromal Tumors › Michigan
Gastrointestinal Stromal Tumors clinical trials in Michigan
7 studies for Gastrointestinal Stromal Tumors are looking for participants at sites in Michigan.
Cities in Michigan
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Profound Research -OMG - TriAtria Cancer Center, Farmington Hills
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06760819A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
- GSK Investigational Site, Ann Arbor
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07218926KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting (SynerGIST-1st Line)
- University of Michigan Hospitals, Ann Arbor
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 10, 2026 · NCT07406633A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies
- START Midwest, Grand Rapids
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 23, 2026 · NCT05957367A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)
- START Midwest, Grand Rapids
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Feb 5, 2026 · NCT06630234A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
- University of Michigan, Ann Arbor
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Feb 5, 2026 · NCT06655246A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
- University of Michigan Hospitals, Ann Arbor
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 23, 2025 · NCT06805825From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.